Render Target: STATIC
Render Timestamp: 2024-10-24T10:42:23.183Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-08-01 15:28:04.050
Product last modified at: 2024-05-30T07:03:21.414Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

CMTM6 Antibody #55829

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY M
    SENSITIVITY Endogenous
    MW (kDa) 22
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CMTM6 Antibody recognizes endogenous levels of total mouse CMTM6 protein. This antibody cross-reacts with an unidentified protein of 35 kDa, 55 kDa, and 75 kDa in some cell extracts.

    Species Reactivity:

    Mouse

    Source / Purification

    Polyclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala176 of mouse CMTM6 protein. Antibodies are purified by peptide affinity chromatography.

    Background

    CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) is a member of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (1). CMTM6 stabilizes plasma membrane expression of PD-L1, an immune inhibitory ligand critical for immune tolerance to self and anti-tumor immunity (2,3). CMTM6 associates with PD-L1 at recycling endosomes, where it protects PD-L1 from being targeted for lysosomal degradation by preventing STUB1-mediated PD-L1 ubiquitination (2,3). CMTM6 may stabilize PD-L1 expression on antigen presenting cells and potentiate inhibitory signaling by PD-1 on T cells, triggering T cell inhibition and exhaustion. CMTM6 has also been shown to interact with CD58, ARG1, ENO1, and TMPO (2). Due to the role of CMTM6 in regulating the immune system, it is being investigated as an immunotherapeutic target for the treatment of cancer.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.